Dr. Assistant Professor
Description
The study included 30 donors and 30 simultaneous recipients who underwent OLT procedure from living donors between 2018 and 2019. The age range of the patients was 19 to 65 years. Participants who had oncological and hematological diseases, coronary or kidney failure, malnutrition, diabetes, traumatic brain injury or cadaveric LT, and who were using psychoactive medicines, having a respiratory system or CNS diseases were excluded from the study. Demographic data of patients, accompanying diseases, ASA classification, main etiology, the recent MELD, and CTP scores were recorded together with laboratory results routinely taken before the operations. During the operations; anesthetic medicines, duration of the operations, anesthesia, prehepatic, anhepatic, post hepatic phases, graft warm ischemia and graft cold ischemia times, initial pulmonary artery pressures, volume replacement treatment features, blood component transfusions, corticosteroid and immunosuppressive medicines administered were recorded. While routine laboratory results were recorded for the patients one day before the operation, plasma ammonia levels were obtained through enzymatic ultraviolet- assay (Randox, VK). Complete blood count (CBS) was performed on an auto-analyzer (Siemens® Advia 2120). Serum biochemical parameters were assayed by standard kit methods using an auto-analyzer (Siemens® Advia 2400). Activated partial thromboplastin time (APTT) and International Normalized Ratio (INR) was determined by an auto-analyzer (Siemens® BCS-XP). Blood samples from patients for NSE and S100β analysis were taken during the preoperative period, in the first and sixth months of the postoperative period. Serum NSE and S100β levels were measured by enzyme-linked immunosorbent assay (ELISA) (LifeSpan BioSciences, Inc. Catalog No. LS-F5575 and Cusabio® Catalog No. CSB-E08065h, respectively). A total of 56 patients with related records have been classified under three groups according to certain criteria. Group 1, healthy donors (group D): 26 patients were recruited as healthy donors. Group 2, end-stage liver failure patients (recipient, group R): 21 recipient patients diagnosed with liver failure. Group 3 (group HE): 9 recipient patients diagnosed with liver failure along with hepatic encephalopathy. Cirrhosis diagnosis was confirmed through MELD and CTP scoring, via biopsy, laboratory findings, and imaging techniques. HE diagnosis, on the other hand, was confirmed by clinical practice and West Haven criteria grading.